SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer

Keyphrases

• Anticancer Agents 100%
• Scavenger Receptor Class B Type 1 (SR-B1) 100%
• Triple-negative Breast Cancer 100%
• Nanodelivery 100%
• Reconstituted High-density Lipoprotein (rHDL) 75%
• High Density Lipoprotein Nanoparticle 50%
• Overexpression 25%
• Treatment Strategy 25%
• High-density Lipoprotein Cholesterol (HDL-C) 25%
• Nanoparticles 25%
• Therapeutic Effect 25%
• Type I Receptor 25%
• Valrubicin 25%
• Cardiomyocytes 25%
• 5-year Survival 25%
• Delivery Agents 25%
• Breast Cancer Patients 25%
• Triple-negative Breast Cancer Cells 25%
• Favorable Prognosis 25%
• Drug Complex 25%
• Survival Prognosis 25%
• Lapatinib 25%
• Hormone Receptor-positive Breast Cancer 25%
• Endocrine Treatment 25%
• Breast Cancer Drugs 25%
• Metastatic Triple-negative Breast Cancer 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 100%
• Breast Cancer 100%
• Scavenger Receptor BI 100%
• Triple Negative Breast Cancer 100%
• High Density Lipoprotein 80%
• Nanoparticle 60%
• Receptor 20%
• Therapeutic Effect 20%
• Valrubicin 20%
• Lapatinib 20%